Compare BVS & MFIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BVS | MFIC |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.2M | 803.1M |
| IPO Year | 2016 | 2004 |
| Metric | BVS | MFIC |
|---|---|---|
| Price | $14.38 | $9.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $14.00 | $11.25 |
| AVG Volume (30 Days) | ★ 810.2K | 613.0K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.84% |
| EPS Growth | ★ 163.46 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $568,087,000.00 | N/A |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $27.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.26 | $9.28 |
| 52 Week High | $15.89 | $13.34 |
| Indicator | BVS | MFIC |
|---|---|---|
| Relative Strength Index (RSI) | 61.47 | 49.56 |
| Support Level | $7.29 | $9.47 |
| Resistance Level | $15.89 | $9.96 |
| Average True Range (ATR) | 0.78 | 0.22 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 51.67 | 71.21 |
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.